Dogwood Therapeutics, Inc. financial data

Symbol
DWTX on Nasdaq
Location
44 Milton Avenue, Alpharetta, GA
State of incorporation
DE
Fiscal year end
December 31
Former names
Virios Therapeutics, Inc. (to 10/15/2024), Virios Therapeutics, LLC (to 12/16/2020)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 482 % -50.6%
Debt-to-equity 26.2 % +129%
Return On Equity -217 % -98%
Return On Assets -172 % -74.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.33M shares -93.1%
Common Stock, Shares, Outstanding 1.11M shares -94.2%
Entity Public Float 24.4M USD -22%
Common Stock, Value, Issued 111 USD -94.2%
Weighted Average Number of Shares Outstanding, Basic 1.11M shares +45.4%
Weighted Average Number of Shares Outstanding, Diluted 1.11M shares +45.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.51M USD -44%
General and Administrative Expense 4.31M USD +16.6%
Operating Income (Loss) -5.82M USD +8.99%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.73M USD +8.22%
Net Income (Loss) Attributable to Parent -5.73M USD +8.22%
Earnings Per Share, Basic -0.67 USD/shares +60.4%
Earnings Per Share, Diluted -0.67 USD/shares +60.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.04M USD -57.4%
Assets, Current 2.28M USD -56.5%
Assets 2.28M USD -56.5%
Accounts Payable, Current 455K USD +122%
Employee-related Liabilities, Current 46.8K USD -82.1%
Accrued Liabilities, Current 879K USD +212%
Liabilities, Current 1.33M USD +174%
Deferred Income Tax Liabilities, Net 216K USD -36.7%
Liabilities 1.33M USD +174%
Retained Earnings (Accumulated Deficit) -66.1M USD -9.48%
Stockholders' Equity Attributable to Parent 949K USD -80.1%
Liabilities and Equity 2.28M USD -56.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -937K USD +44.8%
Common Stock, Shares Authorized 43M shares 0%
Common Stock, Shares, Issued 1.12M shares -94.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.04M USD -57.4%
Deferred Tax Assets, Valuation Allowance 9.93M USD +14.3%
Deferred Tax Assets, Gross 10.1M USD +12.4%
Deferred Tax Assets, Operating Loss Carryforwards 7.13M USD +25.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 67.3M USD +2.93%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 216K USD -36.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%